Alpha-Lipoic Acid Supplement

## What it is Alpha-lipoic acid (ALA, also called thioctic acid) is a short-chain fatty acid containing a disulfide ring that gives it unusual redox properties. The molecule was isolated in 1951 by Lester Reed at the University of Texas during a search for cofactors in pyruvate dehydrogenase. It serves as an essential cofactor for several mitochondrial dehydrogenase complexes, including pyruvate dehydrogenase and alpha-ketoglutarate dehydrogenase. The body synthesizes small amounts endogenously from octanoic acid in mitochondria. Dietary contribution is minimal at typical Western intakes (estimated 1 to 5 mg/day from organ meats, spinach, and broccoli). Oral supplementation delivers substantially higher doses, with 600 mg/day being the most-studied dose for clinical effects. ALA exists as two enantiomers: R-ALA (the natural form, biologically active) and S-ALA (synthetic, less active). Standard supplements sold as 'alpha-lipoic acid' are typically racemic mixtures (50:50 R:S). R-ALA-only supplements (sometimes called 'R-lipoic acid' or 'BioEnhanced R-ALA') are roughly 40 to 100% better absorbed than racemic mixtures and produce higher peak plasma concentrations. The R-ALA price premium runs roughly 2 to 3x. Legally ALA is a dietary supplement in the United States, UK, Canada, and most of the EU. It has prescription drug status in Germany for diabetic neuropathy under the brand Thioctacid (intravenous formulation, 600 mg/day) since the 1960s. The German jurisdictional context is important: the largest and most rigorous neuropathy trials were conducted under European regulatory frameworks, which is why pain-physician knowledge of ALA varies substantially between Germany and the rest of the world. WADA does not list it. ## Mechanism of action ALA's most distinctive property is dual solubility. The disulfide ring and short carbon chain allow it to cross both lipid bilayers (intracellular membranes, blood-brain barrier) and aqueous compartments (cytosol, plasma) without being trapped in either. This enables ALA and its reduced form, dihydrolipoic acid (DHLA), to participate in redox reactions across cellular compartments that other antioxidants cannot reach. The redox cycling between ALA and DHLA is the central pharmacological feature. DHLA can directly scavenge reactive oxygen species, regenerate oxidized vitamin E and vitamin C back to their reduced forms, and chelate transition metals (iron, copper, mercury). The 'universal antioxidant' framing in supplement marketing oversells the practical effect, but the biochemistry is real. At the metabolic level, ALA activates AMPK in liver and skeletal muscle (similar to berberine and metformin), inhibits gluconeogenesis, and increases insulin sensitivity. These effects underlie the diabetic neuropathy and metabolic-marker outcomes. The neuropathy benefit specifically is thought to combine direct antioxidant protection of peripheral nerves from hyperglycemia-induced oxidative stress with improved nerve blood flow through endothelial NO restoration. Oral bioavailability is modest. Racemic ALA in standard formulation has 30 to 40% bioavailability. R-ALA achieves 40 to 60%. Plasma half-life is short (about 30 minutes), with rapid hepatic conjugation and renal excretion. The short half-life is part of why intravenous administration produces larger and more consistent effects than oral administration in neuropathy trials. Oral split dosing (300 mg twice daily) and sustained-release formulations partly compensate for the short half-life. ## Evidence base by outcome ### Diabetic peripheral neuropathy The strongest indication. The ALADIN, ALADIN III, SYDNEY, and SYDNEY 2 trials (combined approximately 1,500 patients) tested ALA at 600 to 1,800 mg/day intravenous or oral for 3 weeks to 6 months and consistently reported improvements in neuropathy symptom scores (Total Symptom Score, Neuropathy Impairment Score). The 2012 Cochrane review supports IV ALA at 600 mg/day for short-term symptom improvement in diabetic neuropathy. Oral ALA shows smaller and less consistent effects, with the NATHAN-1 trial (Ziegler 2011, n=460, oral 600 mg/day for 4 years) showing modest improvements in nerve impairment scores but no significant effect on the primary composite endpoint. ### Insulin sensitivity and HbA1c Meta-analyses report small reductions in fasting glucose (5 to 10 mg/dL) and HbA1c (0.2 to 0.3%) at 300 to 600 mg/day for 8 to 16 weeks in T2DM and prediabetic adults. Effect sizes are smaller than berberine or metformin and the evidence is concentrated in subjects with baseline insulin resistance. ### Body weight The Kucukgoncu 2017 meta-analysis (12 trials, 769 participants) reported a 1.27 kg average weight reduction at 300 to 1,800 mg/day for 8 to 24 weeks. Effect sizes are similar to or slightly smaller than green tea extract or berberine. Real but modest. ### Cardiovascular markers Small reductions in oxidized LDL, hs-CRP, and arterial stiffness measures appear at 600 to 1,800 mg/day. Hard cardiovascular endpoint trials are absent. C-tier on cardiovascular outcomes despite biologically plausible mechanisms. ### Cognitive function Limited but suggestive evidence. Small trials in mild cognitive impairment and Alzheimer disease at 600 mg/day report small improvements in cognitive scores or slowed decline. The combined ALA + omega-3 trial in mild AD (Shinto 2014, n=39, 12 months) showed slowed decline on MMSE versus placebo. Single-trial evidence; C to D-tier. ### Multiple sclerosis Small pilot trials have suggested benefit on brain atrophy progression in relapsing-remitting MS. The Spain 2017 trial (n=51, ALA 1,200 mg/day for 2 years) reported reduced annualized brain atrophy versus placebo. Single-trial evidence; C-tier. ### Burning mouth syndrome Several small trials in this idiopathic pain syndrome at 600 mg/day for 2 months reported pain reductions versus placebo. C-tier; reasonable trial in this otherwise difficult-to-treat condition. ### Heavy metal chelation ALA chelates mercury, lead, and arsenic in vitro and shows modest efficacy in animal models. Human clinical evidence for chelation therapy is limited. The biohacker use of ALA for heavy metal detoxification runs ahead of the trial evidence. ## Dosage and protocols Standard dose ranges: - Diabetic neuropathy: 600 to 1,800 mg/day oral; 600 mg/day IV in clinical settings (Germany) - Metabolic and antioxidant general use: 300 to 600 mg/day - R-ALA only: 100 to 300 mg/day (lower dose due to better absorption) Take on an empty stomach when possible. Food substantially reduces ALA absorption (roughly 30 to 50%), and this is one of few supplements where fasted dosing is the standard recommendation. Take 30 minutes before meals or 2 hours after. Split dosing 2 to 3 times daily improves steady-state plasma exposure given the short half-life. Sustained-release formulations are available and reasonable for once-daily dosing convenience. Biotin co-administration is recommended for chronic ALA use. ALA structurally resembles biotin and competes with biotin uptake; chronic high-dose ALA can induce biotin insufficiency over months. A standard B-complex or 100 to 300 mcg biotin daily prevents the issue. No cycling required for typical metabolic and antioxidant indications. Some users cycle 12 weeks on, 4 weeks off, mostly on theoretical grounds rather than evidence-based concern. ## Side effects and safety GI side effects (nausea, abdominal discomfort, diarrhea) affect 10 to 20% of users at 600 mg/day or above. Splitting the dose and starting at 300 mg/day for the first week reduces incidence. Sulfur-containing odor and taste are inherent to the molecule. Capsules largely avoid the taste; bulk powders are unpleasant. Hypoglycemia is the most clinically important safety concern. ALA increases insulin sensitivity and can produce additive hypoglycemia in patients on insulin or sulfonylureas. Monitor blood glucose carefully when starting or adjusting doses; some patients require reduction of antidiabetic medications. Insulin autoimmune syndrome (Hirata disease) has been reported in genetically predisposed individuals (HLA-DRB1*04:06, more common in Japanese and Asian populations) taking ALA. The condition produces severe hypoglycemia from anti-insulin antibodies. Rare but serious; warrants attention to recurrent unexplained hypoglycemia. Thyroid effects: ALA can suppress thyroid hormone conversion (T4 to T3) at high doses. Patients on thyroid replacement may need dose adjustment. Pregnancy and lactation use is precautionary. Limited safety data. Avoid at supplement doses unless benefit clearly outweighs unknown risk. Drug interactions worth noting: insulin and oral hypoglycemics (additive hypoglycemia, dose adjustment may be required); thyroid hormone (possible reduction in T3 conversion); chemotherapy agents (theoretical interference with oxidative-stress-dependent agents). ## Stack interactions and timing ALA pairs naturally with biotin (offsets the antagonism on biotin uptake), with omega-3 fatty acids in cognitive aging stacks, and with acetyl-L-carnitine in mitochondrial supplementation protocols (the Hagen 2002 rat aging study used ALA + acetyl-L-carnitine and is the foundational work for the combination). Avoid combining with high-dose iron supplementation; ALA chelates iron and reduces absorption. Morning dosing on an empty stomach is the conventional pattern. Splitting morning and afternoon improves steady-state exposure. Avoid late evening dosing in patients on glucose-lowering medications. ## Practical notes Form matters. R-ALA-only formulations are better absorbed than racemic mixtures and produce higher plasma concentrations. The price premium runs 2 to 3x. For users prioritizing trial-replication doses, R-ALA at 100 to 300 mg/day is comparable to racemic at 300 to 600 mg/day. Quality varies. Look for products that specify R-ALA content (versus total ALA), provide third-party testing, and are sealed in nitrogen-flushed packaging. ALA oxidizes on exposure to air and moisture. Cost is moderate. Racemic ALA runs 5 to 15 cents per 100 mg; R-ALA runs 15 to 40 cents per 100 mg. A 600 mg/day racemic protocol runs roughly 30 cents to 1 dollar per day. Storage matters. ALA is light- and oxygen-sensitive. Keep in original packaging, away from heat and humidity. Discard if the product develops a strongly sulfurous smell or yellowed color, indicating oxidation. Expect biomarker effects (oxidized LDL, glycemic markers) within 4 to 8 weeks. Symptomatic effects on neuropathy typically appear within 4 to 12 weeks of consistent dosing. Pain reduction in burning mouth syndrome typically requires 6 to 8 weeks.